A group at the Lawrence Berkeley National Laboratory believes that a synthetic antioxidant previously shown to reduce apoptosis and enhance cell survival in vitro can ameliorate the symptoms of Huntington’s Disease – and beyond its neuroprotective effects, may even have disease modifying properties. They’ve published the first proof of concept in animals, aiming to bring the compound into human studies.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.